1. Which component of an antibody-drug conjugate (ADC) can influence its toxicity profile?

2. DG is a 34-year-old patient with metastatic triple-negative breast cancer. She has progressed on multiple previous lines of chemotherapy and the team is looking to start her on a new novel ADC. Which of the following therapies is most appropriate for DG?

3. PM just received education on a new ADC and is concerned with the possibility of not being able to drive due to loss of visual acuity associated with this new therapy. What therapy did PM most likely learn about?

Evaluation Questions

4. How confident are you in your treatment choice for DG?

« Return to Activity